Humana (HUM) Gets a Buy Rating from Barclays

By Carrie Williams

In a report issued on December 6, Steven Valiquette from Barclays maintained a Buy rating on Humana (HUMResearch Report), with a price target of $358.00. The company’s shares closed last Monday at $348.14, close to its 52-week high of $350.46.

According to TipRanks.com, Valiquette is a 4-star analyst with an average return of 5.2% and a 57.0% success rate. Valiquette covers the Services sector, focusing on stocks such as Patterson Companies, Molina Healthcare, and Diplomat Pharmacy.

Humana has an analyst consensus of Moderate Buy, with a price target consensus of $343.50.

See today’s analyst top recommended stocks >>

Humana’s market cap is currently $46.1B and has a P/E ratio of 18.50. The company has a Price to Book ratio of 3.97.

Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HUM in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Humana Inc. engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty, Healthcare Services, and Individual Commercial.